The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

Research shows older adults had 4.45 million skin cancer cases in 2021. Basal cell carcinoma is expected to double by 2050 worldwide.

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice ...

Increasing the cholesterol-lowering protein ApoM in mice improved retinal health and may be the key to slowing age-related ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance ...

Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.

Investigators have identified the lowest dose of the immunosuppressive ATG needed to preserve beta cells in newly diagnosed children with Type 1 diabetes with the lowest side effects.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.